Day: October 3, 2024

A EUR 16 million Initiative to Establish Strategic EU Autonomy in Alpha Therapies for Cancer Louvain-la-Neuve, Belgium, October 3, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, is pleased to announce that the European Commission has approved the financing of the Accelerate.EU project launching on October 1, 2024. IBA’s key role in this new project further reiterates its market leading role in supporting the production of novel targeted alpha therapies for cancer. As the industry leader of the Accelerate.EU initiative, IBA will facilitate the development of a production network to enable greater access to targeted alpha therapy across the EU through the development of a new alpha-machine cyclotron as an...

Saint Herblain (France), October 3, 2024 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will host an investor day at the Lotte New York Palace Hotel in New York, NY on Thursday, October 10, 2024 at 10:00 AM ET (4:00 pm CET). The meeting will be conducted in a hybrid way – in person and webcast. To register, click here. The event will focus on Valneva’s robust R&D pipeline of potentially first-, only-, or best-in-class vaccine candidates addressing major unmet medical needs in infectious disease: Lyme disease (Phase 3, led by Pfizer), Shigella (Phase 2), and Zika (Phase 1). It will also highlight Valneva’s growing portfolio of revenue-generating vaccines, including the launch of the world’s first and only approved vaccine against chikungunya virus. Speakers from Company management...

TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) — KMT-Hansa Corp. (the “Corporation”) is pleased to announce that it has negotiated various debt conversion agreements (collectively, the “Debt Agreements”) with 7 creditors (collectively, the “Creditors”), all of which are arm’s length parties to the Corporation. Pursuant to the terms of the Debt Agreements, the Corporation has agreed to issue an aggregate of up to 28,571,428 common shares (“Debt Shares”) to the Creditors in exchange for the cancellation of up to $1 million in debt owing to the parties. The Debt Shares are being issued at a deemed price of $0.035 per Debt Share. The Debt Shares issued pursuant to the Debt Agreements are subject to a statutory four (4) month hold period. For further information please contact: Jay VieiraDirector and Chief Executive Officer Email: kmthansa@gmail.com Neither...

EAGLE, Idaho, Oct. 02, 2024 (GLOBE NEWSWIRE) — The Pennant Group, Inc. (NASDAQ: PNTG) (the “Company”) today announced the pricing of an underwritten public offering of 3,500,000 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $108.5 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock. The Company expects to use the net proceeds from the offering to repay outstanding indebtedness under the Company’s revolving credit facility and any remaining for general corporate purposes. The offering is expected to close on or about October 4, 2024, subject to customary closing conditions. Citigroup...